Skip to main content
. 2019 Dec 21;11(2):497–504. doi: 10.1002/jcsm.12507

Figure 2.

Figure 2

Kaplan–Meier cumulative incidence plot for geriatric adverse outcome including mortality and institutionalization during observation period, by baseline sarcopenic status. (A) Original (EWGSOP 1) and revised (EWGSOP 2) European consensus for sarcopenia—(A) no sarcopenia by either EWGSOP 1 or EWGSOP 2; (B) sarcopenia by EWGSOP 1 but not considered as sarcopenic by EWGSOP 2; (C) sarcopenia, not severe, by EWGSOP 2; and (D) severe sarcopenia by EWGSOP 2 (log‐rank P < 0.001). (B) newly proposed sarcopenia phenotype score—(A) sarcopenia phenotype score of 0; (B) sarcopenia phenotype score of 1; (C) sarcopenia phenotype score of 2; and (D) sarcopenia phenotype score of 3/3 (log‐rank P < 0.001). EWGSOP, European Working Group on Sarcopenia in Older People.